Online inquiry

IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12289MR)

This product GTTS-WQ12289MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Merkel cell carcinoma (MCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12289MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4891MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ12597MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ14183MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ6257MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ1283MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ8354MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ9759MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ3517MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BART
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW